JULIE VATTE

Dr. JULIE VATTE


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2024 in Molecules
Verified
Journal Article
Open access
PDF file
JVJULIE VATTE
JULIE VATTE
VBVéronique Bourdeau
Véronique Bourdeau
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre
ASAndreea Ruxandra Schmitzer
Andreea Ruxandra Schmitzer
AUTAC-Biguanide is a hybrid compound designed to target mitochondria, inducing their degradation by mitophagy. This study unveils the potential of biguanides as cancer cell-targeting agents, emphasizing AUTAC-Biguanide’s superior antiproliferative properties compared to metformin and its selectivity for cancer cells. The mechanism behind this heightened effect includes the ability of AUTAC-Biguanide to trigger mitophagy. By providing a comprehensive analysis of these findings, this study adds valuable insights to the field of mitochondrial-targeting anticancer agents.

12 November 2024 in Molecules
Verified
Journal Article
Open access
PDF file
JVJULIE VATTE
JULIE VATTE
VBVéronique Bourdeau
Véronique Bourdeau
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre
ASAndreea Ruxandra Schmitzer
Andreea Ruxandra Schmitzer
This study focuses on the synthesis of Biguanide-PROTACs, formed by conjugating the biguanide motif with a spacer and a ligand for recognition subunits of two E3 ubiquitin ligases. Evaluation of their activity on pancreatic cancer cell (KP4) proliferation established a correlation between membrane permeability and median effective concentration. Mechanistic insights revealed that only two compounds exhibited biguanide-like AMPK activation, while only one hydrophobic compound uniquely altered mitochondrial protein levels. The prospect of developing and expanding the Biguanide-PROTAC library holds several promises, offering potential insights into biguanide mechanisms and the creation of more potent anticancer agents. This study contributes to understanding the intricate interplay between compound structure, permeability, and anticancer activity, paving the way for targeted drug development in pancreatic cancer treatment.

15 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
JVJULIE VATTE
JULIE VATTE
VBVéronique Bourdeau
Véronique Bourdeau
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre
ASAndreea Ruxandra Schmitzer
Andreea Ruxandra Schmitzer
AUTAC-Biguanide is a hybrid compound designed to target mitochondria inducing their degradation by mitophagy. This study unveils the potential of biguanides as cancer cell-targeting agents, emphasizing AUTAC-Biguanide's superior antiproliferative properties compared to metformin and its selectivity for cancer cells. The mechanism behind this heightened effect includes the ability of AUTAC-Biguanide to triggers mitophagy. By providing a comprehensive analysis of these findings, the study adds valuable insights to the field of mitochondrial-targeting anticancer agents.